The Race — Building Democracy in the Age of AI. People race toward a shared finish line.
The Race
← Specific Events

United States

Scorecard

FDA opens public process to design regulation of generative-AI medical devices — August 18, 2026

What happened

The U.S. Food and Drug Administration opened docket FDA-2026-N-7874 seeking public input on potential regulatory approaches for generative-AI-enabled medical devices. FDA’s discussion paper raises specific questions concerning risk assessment, premarket competency evaluation, postmarket monitoring, foundation models, and agentic AI systems. Manufacturers, clinicians, researchers, consumers, and other members of the public may submit comments through October 19, 2026.

Potential direction of power

Mixed-contested

Window of contestability

Opens

FDA has exposed consequential regulatory design questions before adopting even draft regulatory expectations and established a formal public docket through which outside actors can provide input. FDA explicitly describes the process as seeking early outside input to inform development of its approach. The later contestability test will be whether subsequent guidance or regulation visibly reflects and responds to competing stakeholder submissions.

Supporting sources

  1. fda.gov · Supporting source 1 ↗